2026-10-15T11:11:53Z https://data.mendeley.com/oai

oai:data.mendeley.com/92gnf9vdd6.1 2026-06-22T17:40:08Z

Dlouha, Dana miRNA profile in HeFH and non-FH patients treated with PCSK9 inhibitor Mendeley Data Our study aimed to characterize changes in the circulating miRNome during one year of treatment with the monoclonal antibodies alirocumab or evolocumab and to compare these changes between HeFH patients and non-FH patients. We hypothesized that PCSK9i therapy would induce distinct alterations in circulating miRNA profiles reflecting differences in lipid metabolism, inflammatory signaling, and cardiovascular risk-related pathways between HeFH and non-FH patients. microRNA Molecular Genetics Epigenetics Familial Hypercholesterolemia Dataset doi:10.17632/92gnf9vdd6.1 oai:data.mendeley.com/92gnf9vdd6.1 Creative Commons Attribution 4.0 International http://creativecommons.org/licenses/by/4.0 https://data.mendeley.com/datasets/92gnf9vdd6 2026-06-22T17:40:08Z